Status:
COMPLETED
Effect of omega3 on Congestive Heart Failure
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Heart Failure Congestive
Eligibility:
All Genders
3-73 years
Phase:
NA
Brief Summary
In this double blinded study patients with resynchronization pacemaker- AICD were assigned to Omega3 and placebo randomly, results indicated that Omega3 had no more effect than placebo in mortality, B...
Detailed Description
Introduction: Widely used as lipid lowering agents, Omega 3 fatty acids have been demonstrated to possess the potential to reduce the risk of cardiovascular events in patients suffering from chronic h...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- EF\< 40%
- sinus rhythm
- accept randomization
- having tri-chamber pacemaker
- Exclusion criteria:
- survival less than 6 months
- class IV heart failure
- using drugs other than study protocol
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01227837
Start Date
October 1 2008
End Date
March 1 2010
Last Update
October 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shiraz University of Medical Sciences
Shiraz, Fars, Iran, 55318